While a 2.5 mg/kg dose of a miR-122 inhibitor was able to normalize Cyp7a1 protein, a larger dose of the miR-122 mimic may have been needed to replicate IUGR+HFD pathophysiology in our rat model. Here, CYP7A1 is linked to fetal growth restriction.